Guggenheim initiates coverage on Climb Bio with Buy rating
Guggenheim analyst Yatin Suneja initiated coverage on Climb Bio with a Buy rating and a price target of $35, signaling a positive outlook for the NASDAQ-listed stock.
*this image is generated using AI for illustrative purposes only.
Guggenheim analyst Yatin Suneja has initiated coverage on Climb Bio with a Buy rating and a price target of $35. The rating highlights a positive outlook for the company's stock performance.
Analyst Details
The coverage initiation comes from Yatin Suneja, an analyst at Guggenheim. The firm set a specific price target to guide investor expectations.
Stock Information
Climb Bio trades on the NASDAQ under the ticker symbol CLYM.
What upcoming clinical milestones could drive Climb Bio's stock toward the $35 price target?
How might competitor developments impact Climb Bio's market position and valuation?
What are the potential risks that could prevent Climb Bio from meeting Guggenheim's expectations?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
